BeOne Medicines Ltd. (ONC) stock
Close on Nov 11, 2026Market cap $47.75BP/E 53.8Yield –
BeOne Medicines Ltd. grew revenue 32.9% to $6.61B over the twelve months to Sep 30, 2026. Operating income rose 545.2% to $1.18B, moving the operating margin from 3.7% to 17.8%. Free cash flow was $1.45B, up 166.1% from a year earlier. At the latest close the market valued the company at $47.75B, 53.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $47.75B
- P/E ratio
- 53.8
- Price to sales
- 7.23
- Price to book
- 8.20
- Dividend yield
- –
- Free cash flow yield
- 3.03%
Fundamentals
- Revenue
- $6.61B
- Net income
- $915.57M
- EPS, diluted
- $0.60
- Free cash flow
- $1.45B
- Book value per share
- $3.82
- Diluted shares
- 1.52B
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $424.00
- Open
- $418.80
- Day's range
- $415.93 – $421.57
- Volume
- 486,212
- Average volume (20 days)
- 491,431
- Beta (5 years)
- 1.05
- 52-week range
- $253.95 – $424.73
- RSI (14 days)
- 70.0
- Volatility (1 year)
- 35.8%
- Relative volume
- 1.20×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ONC | S&P 500 | Difference | ONC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +18.5% | -2.4% | +20.9 pts | ||
| 3 months | +16.9% | -1.2% | +18.0 pts | ||
| Year to date | +38.2% | +12.3% | +25.9 pts | ||
| 1 year | +22.2% | +12.4% | +9.8 pts | ||
| 3 years | +110.9% | +78.8% | +32.1 pts | +28.2% | +21.4% |
| 5 years | +13.9% | +75.2% | −61.2 pts | +2.6% | +11.9% |
| 10 years | +1204.3% | +311.1% | +893.2 pts | +29.3% | +15.2% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BeOne Medicines filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Results
About BeOne Medicines
Pharmaceutical Preparations
BeOne is a global biopharmaceutical organization focused on discovering, developing, and commercializing treatments for cancer patients worldwide. The enterprise concentrates its clinical pipelines and commercial activities primarily on hematology and solid tumor oncology. Its commercialized portfolio includes internally developed therapies such as the Bruton's tyrosine kinase inhibitor BRUKINSA, the anti-PD-1 monoclonal antibody TEVIMBRA, the B-cell lymphoma 2 inhibitor sonrotoclax, and the PARP inhibitor PARTRUVIX, alongside various in-licensed therapies covering diverse hematologic and solid malignancies. Its customer base consists of healthcare systems, hospitals, and cancer patients accessing therapies through public and private healthcare reimbursement frameworks.
Company profile, executives and historyBeOne Medicines stock: common questions
What is BeOne Medicines's stock price?
ONC closed at $419.98 on Nov 11, 2026, down 0.95% on the day. Over the past 52 weeks it traded between $253.95 and $424.73.
What is BeOne Medicines's market cap?
BeOne Medicines was worth $47.75B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ONC's P/E ratio?
ONC trades at 53.8 times earnings, based on diluted earnings per share of $0.60 over the twelve months to Sep 30, 2026.
How much revenue does BeOne Medicines make?
BeOne Medicines reported revenue of $6.61B for the twelve months to Sep 30, 2026, up 32.9% from a year earlier.
Does BeOne Medicines pay a dividend?
No. BeOne Medicines has not paid a cash dividend over the last twelve months.
When does BeOne Medicines report earnings next?
BeOne Medicines is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ONC stock performed over the past year?
Including dividends, ONC returned +22.2% over the past year, against +12.4% for the S&P 500.
Who are BeOne Medicines's competitors?
Companies most similar to BeOne Medicines by business, industry and size include GRFS, JAZZ, OGN, ALNY, TEVA.
See a number that looks wrong?